Nkarta Therapeutics News and Activities
Presence
Nkarta Therapeutics develops cell therapies for cancer. Its main products include NK cell treatment candidates and research platforms for hospitals, cancer centers, and patients with blood and solid tumor diseases.
Nkarta Therapeutics products and services overview:
- Cell therapies
- Cancer treatments
- NK cell therapies
- Immunotherapy platforms
Revenue: ~$0 million
Employees: 170
Headquarters: South San Francisco, United States (USA)
Nkarta Therapeutics is one of the...
Nkarta Therapeutics is a company listed under the stock ticker NKTX (US).
Executives
View the org chart displaying its 12 main executives
Most searched biographies at Nkarta Therapeutics
- Paul Hastings, Chief Executive Officer and Director
- Zach Scheiner, Director
- Angela Thedinga, Director
Popular executive movements at Nkarta Therapeutics
- Suzanne Vyvoda has joined the company as Senior Vice President, Development Operations (posted on May 21 2026).
Create your alert
to follow the executive moves at Nkarta Therapeutics.
Biotechnology
Nkarta Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Nkarta Therapeutics
- Nkarta Announces Key Senior Leadership Team Appointments | Nkarta, Inc.
- Press Releases | Nkarta, Inc.
- Press Releases | Nkarta, Inc.
- Nkarta to Participate at Upcoming Investor Conference | Nkarta, Inc.
- Press Releases | Nkarta, Inc.
Social media about Nkarta Therapeutics
- Nkarta Therapeutics on Wikipedia, Google News & Yahoo Finance
- Nkarta Therapeutics on LinkedIn, X (Twitter) & YouTube
